In addition, inhibition of the SREBP1-dependent enzyme ACLY has been reported to enhance the efficacy of tamoxifen in breast cancer cells; ACLY additionally is a potential biomarker for predicting breast cancer recurrence [77,78]. Here, ACLY is linked to breast cancer.